CA2019218A1 - Conjugats de proteine magnetiques, procede de preparation et utilisation - Google Patents

Conjugats de proteine magnetiques, procede de preparation et utilisation

Info

Publication number
CA2019218A1
CA2019218A1 CA2019218A CA2019218A CA2019218A1 CA 2019218 A1 CA2019218 A1 CA 2019218A1 CA 2019218 A CA2019218 A CA 2019218A CA 2019218 A CA2019218 A CA 2019218A CA 2019218 A1 CA2019218 A1 CA 2019218A1
Authority
CA
Canada
Prior art keywords
preparation
protein conjugates
cells
magnetic protein
removal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2019218A
Other languages
English (en)
Other versions
CA2019218C (fr
Inventor
Peter Hermentin
Reiner Donges
Udo Franssen
Karlheinz Enssle
Heinz-Jurgen Friesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of CA2019218A1 publication Critical patent/CA2019218A1/fr
Application granted granted Critical
Publication of CA2019218C publication Critical patent/CA2019218C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/20—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations containing free radicals, e.g. trityl radical for overhauser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/90—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids characterised by small molecule linker used to couple immunoreagents to magnetic particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002019218A 1989-06-19 1990-06-18 Conjugats de proteine magnetiques, procede de preparation et utilisation Expired - Fee Related CA2019218C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3919873A DE3919873A1 (de) 1989-06-19 1989-06-19 Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung
DEP3919873.1 1989-06-19

Publications (2)

Publication Number Publication Date
CA2019218A1 true CA2019218A1 (fr) 1990-12-19
CA2019218C CA2019218C (fr) 2001-01-02

Family

ID=6382977

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002019218A Expired - Fee Related CA2019218C (fr) 1989-06-19 1990-06-18 Conjugats de proteine magnetiques, procede de preparation et utilisation

Country Status (12)

Country Link
US (1) US5095097A (fr)
EP (1) EP0403961B1 (fr)
JP (1) JP2858883B2 (fr)
KR (1) KR0154120B1 (fr)
AT (1) ATE102052T1 (fr)
AU (1) AU639867B2 (fr)
CA (1) CA2019218C (fr)
DE (2) DE3919873A1 (fr)
DK (1) DK0403961T3 (fr)
ES (1) ES2063200T3 (fr)
IE (1) IE63666B1 (fr)
PT (1) PT94398B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2593192A (en) 1992-09-14 1994-04-12 Oystein Fodstad Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
NO180658C (no) * 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5585278A (en) * 1994-10-27 1996-12-17 Bayer Corporation Method for coupling antibody to novel latex substrate and its use in immunoassay
WO1997014443A1 (fr) * 1995-10-19 1997-04-24 Bracco International B.V. Substances chimiotactiques marquees magnetiquement comme agents de contraste pour l'imagerie par rmn de tissus vivants cibles
NO961031D0 (no) 1996-03-13 1996-03-13 Det Norske Radiumshospital Tum Fremgangsmåte til å drepe uönskede målceller
WO1997036008A1 (fr) * 1996-03-26 1997-10-02 Biotechnology Transfer, Inc. Techniques de mesure de la fonction lymphocytaire
JP3662347B2 (ja) * 1996-06-10 2005-06-22 日鉄鉱業株式会社 医療用粉体
US6379975B1 (en) * 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
US7169571B2 (en) 1997-09-12 2007-01-30 Cylex, Inc. Methods for measurement of lymphocyte function
US6828157B1 (en) 1999-05-04 2004-12-07 Dan A. Pankowsky Products and methods for single parameter and multiparameter phenotyping of cells
US6682940B2 (en) 1999-05-04 2004-01-27 Dan A. Pankowsky Products and methods for single parameter and multiparameter phenotyping of cells
EP1181551B1 (fr) * 1999-05-04 2006-10-25 Dan A. Pankowsky Produits et methodes utilisant un parametre unique ou plusieurs parametres pour determiner des phenotypes de cellules
CN1488073A (zh) * 2001-04-17 2004-04-07 西莱克斯公司 利用促细胞分裂原和抗原测定淋巴细胞活化的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2334106A1 (fr) * 1975-12-02 1977-07-01 Pasteur Institut Gel magnetique convenant pour dosages immunoenzymatiques
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
NO155316C (no) 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US4554088A (en) 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US4698302A (en) * 1983-05-12 1987-10-06 Advanced Magnetics, Inc. Enzymatic reactions using magnetic particles
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4814098A (en) * 1986-09-06 1989-03-21 Bellex Corporation Magnetic material-physiologically active substance conjugate

Also Published As

Publication number Publication date
EP0403961B1 (fr) 1994-03-02
ES2063200T3 (es) 1995-01-01
ATE102052T1 (de) 1994-03-15
IE902194A1 (en) 1991-01-02
IE63666B1 (en) 1995-05-31
EP0403961A3 (fr) 1991-07-17
DK0403961T3 (da) 1994-06-27
IE902194L (en) 1990-12-19
AU5717890A (en) 1990-12-20
JP2858883B2 (ja) 1999-02-17
JPH03184999A (ja) 1991-08-12
DE59004731D1 (de) 1994-04-07
AU639867B2 (en) 1993-08-05
EP0403961A2 (fr) 1990-12-27
US5095097A (en) 1992-03-10
KR0154120B1 (ko) 1998-10-15
PT94398B (pt) 1997-01-31
CA2019218C (fr) 2001-01-02
PT94398A (pt) 1991-02-08
KR910000797A (ko) 1991-01-30
DE3919873A1 (de) 1990-12-20

Similar Documents

Publication Publication Date Title
CA2019218A1 (fr) Conjugats de proteine magnetiques, procede de preparation et utilisation
AU4515885A (en) New tetrapyrrole therapeutic agents
WO1995033497B1 (fr) Agents chelateurs metalliques a base de thiol, diamide et monoamine
HK1038306A1 (en) Strategically modified hepatitis b core proteins and their derivatives
AU6609786A (en) Contrast agents for ultrasonic imaging
ES488888A1 (es) Procedimiento de fabricacion de una suspension acuosa de alumina
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
AU4548189A (en) Glycosphingolipids with a group capable of coupling in the sphingoid portion, the preparation and use thereof
IE902195L (en) Magnetic protein conjugates
YU49189A (en) Magnetic proteinic conjugates, process for preparing and use thereof
EP0388356A3 (fr) Lentilles absorbant l'ultraviolet et leurs méthodes de fabrication
WO1995029708B1 (fr) AGENTS D'IMAGERIE MARQUES AU TECHNETIUM 99m
AU7556487A (en) Immunotoxins, process for their preparation and pharmaceutical compositions in which they are present
ZA904565B (en) Peptides and antibodies derived therefrom for the diagnosis of therapy for and vaccination against htlv-1 infection
EP0110688B1 (fr) Production de facteurs angiogéniques
EP0342989A3 (fr) Composés polymaléimiques et procédé pour leur préparation
DE3370026D1 (en) Biologically active conjugates and their preparation and use
EP0096932A3 (en) Process for making a lyophilized product for use in skeletal imaging
CA2411019A1 (fr) Particules pour les dosages immunologiques et methodes de traitement de ces particules
GB8906708D0 (en) Improvements relating to the radiolabelling of proteins
EP0373613A3 (fr) Monopersulfate de l'acide pyridine-3-percarboxylique
EP0194563A3 (fr) Glycosides et leur procédé de préparation
HUT38832A (en) Agent suitable for increasing the ph-value of tooth-plaque and process for producing the same
JPS6470490A (en) Mitomycins and production thereof
FR2559157B1 (fr) Nouvel hexapeptide, son procede d'obtention et les compositions pharmaceutiques qui le contiennent

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed